Treatment Choice and Long-Term Outcome in Paediatric Autoimmune Encephalitis

Activity: Talk or presentation types › Oral presentation

Description

Autoimmune encephalitis (AE) is an important and treatable cause of acute CNS inflammation. Majority children have favourable prognosis with slow recovery, however significant part may have long-term complications. Our study aim was to describe our AE patient cohort received treatment and respective long-term outcome. . This was a retrospective study and included Children’s Clinical University Hospital patients with diagnosed autoimmune encephalitis (AE) starting from 2014 till 2022. Information about treatment choice and long-term outcome were collected from medical history data system. . In our study group 16 patients were enrolled, annual AE incidence was ranging 0 – 1.67 /100 000 children in the analysed study years. Mean age in study group was 8.0 ± 5.6 years, 56.2% (n=9) were males, 43.8% (n=7) females. Mean hospital days stay till diagnosis and treatment initiation was 6.2 ± 5.2 days. Received first-line treatment was: IVIG+IVMP in 43.8% (n=7), IVMP in 25.0% (n=4), IVIG in 25.0% (n=4), or PEX with IVMP (n=1) or with IVIG+IVMP (n=1), missing data n=1. Mean days from first to second line treatment was 18.4 ± 8.7 days. Second-line treatment was initiated in 43.8% (n=7): rituximab (n=4), cyclophosphamide (n=1) or both (n=2). More than half 62.5% (n=10) of study group had long term sequels: 4/9 patients in first-line treatment only, 6/7 patients in second-line treatment group. Length in days since symptom onset till treatment initiation was not associated with higher probability of long-term complications (p > 0.05). Rest of the study group (n=6) became symptom free in mean 17.7 ± 16.2 days. . Most common first-line treatment was combination of IVIG and IVMP. Almost half of patients needed to recieve second-line treatment, most frequent choice was rituximab. More than half of patients had long-term complications. Early second-line treatment initiation may be favorable for children diagnosed with AE.
Period29 Mar 2023
Event titleRSU International Research Conference 2023: Knowledge for Use in Practice
Event typeConference
OrganiserRīga Stradiņš University
LocationRiga, LatviaShow on map
Degree of RecognitionInternational

Related content